Tirzepatide vs Semaglutide: Research Comparison
Both peptides are household names in metabolic research. Here’s how they compare:
Mechanism
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 (dual) |
| Class | Single agonist | Dual agonist |
| Half-life | ~7 days | ~5 days |
| Molecular weight | 4113.6 Da | 4813.6 Da |
Research Outcomes
Semaglutide
- PIONEER trials (oral), SUSTAIN trials (injectable)
- Strong HbA1c reduction (~1.5-1.8%)
- Weight loss: ~6-15% depending on dose
- Cardiovascular benefit (SUSTAIN-6)
Tirzepatide
- SURPASS trials (head-to-head vs. semaglutide)
- Superior HbA1c reduction (~2.0-2.3%)
- Weight loss: ~15-22% (SURMOUNT trials)
- First dual-agonist approved for T2D
Synthesis Differences
The molecular structure matters for sourcing:
- Semaglutide: Modified GLP-1 with C18 fatty acid side chain
- Tirzepatide: Synthetic peptide with C20 fatty diacid side chain
- Both require SPPS + careful purification to remove truncated sequences
Choosing for Research
Researchers often work with both because:
- Tirzepatide may show greater weight loss in obesity models
- Semaglutide has more long-term cardiovascular data
- Mechanism comparison is scientifically valuable
Conclusion
Both peptides are now standard tools in metabolic research. The choice depends on your specific research question and budget.
Order from Jike Bio: Both available in 5mg-30mg vials with ≥99% HPLC.